Harnessing Endogenous Mechanisms for Targeted Drug Delivery presents a comprehensive exploration of the evolving landscape of targeted drug delivery, emphasizing the strategic utilization of the body's intrinsic biological pathways. This authoritative two-volume reference addresses the critical need for precision in therapeutic delivery, overcoming physiological, anatomical, and immunological barriers through innovative endogenous mechanisms. By integrating foundational concepts with advanced methodologies, the work underscores the transition from traditional passive and active targeting to sophisticated endogenous strategies that enhance drug specificity and efficacy.
The text systematically examines the multifaceted challenges inherent in drug delivery, including detailed analyses of in vivo barriers such as the blood-tumor barrier, blood-brain barrier, ocular, pulmonary, and gastrointestinal obstacles, as well as cellular and intracellular impediments. It further elucidates endogenous stimuli-responsive systems, nutrient transporter exploitation, glyco-targeting, and stealth peptide modifications. Comprehensive coverage extends to drug conjugates, protein corona phenomena, and cell-based delivery platforms encompassing stem cells, leukocytes, erythrocytes, and platelets. The series also addresses extracellular vesicles, viral vectors, and plant virus-based carriers, culminating in critical discussions on manufacturing complexities, regulatory considerations, and clinical translation challenges.
This definitive resource is indispensable for graduate students, postdoctoral researchers, and professionals in academia and industry engaged in targeted drug delivery research and development. By providing an in-depth understanding of endogenous targeting mechanisms and their translational potential, the book fosters innovation and supports the advancement of precision therapeutics with the goal of improving patient outcomes.
1. Chapter One. Introduction and impact statement - p. 3 2. Chapter Two. Challenges and opportunities in targeted delivery - p. 5 3. Section 2. Delivery barriers - p. S2 4. Chapter Three. Blood–tumor barriers - p. 15 5. Chapter Four. The blood–brain barrier - p. 49 6. Chapter Five. Overcoming ocular barriers for effective drug delivery - p. 85 7. Chapter Six. Pulmonary barriers to targeted delivery - p. 111 8. Chapter Seven. Exploiting gastrointestinal barriers for targeted drug delivery - p. 149 9. Chapter Eight. Cellular and intracellular barriers for drug delivery - p. 189 10. Section 3. Endogenous targeting strategies - p. S3 11. Chapter Nine. Overview of endogenous targeted delivery strategies - p. 219 12. Chapter Ten. Endogenous pH alterations for precision drug delivery - p. 267 13. Chapter Eleven. Hypoxia responsive delivery systems - p. 307 14. Chapter Twelve. Redox-responsive micellar drug delivery systems - p. 341 15. Chapter Thirteen. Nutrient transporter-targeted drug delivery - p. 361 16. Chapter Fourteen. Glyco-targeted delivery systems - p. 395 17. Chapter Fifteen. Surface-modified delivery systems for stealth function - p. 421 18. Section 4. Drug conjugates - p. S4 19. Chapter sixteen. Therapeutic exploitation of the neonatal Fc receptor in albumin-based drug designs - p. 443 20. Chapter Seventeen. Lectin conjugates for targeted delivery - p. 471 21. Section 5. Protein corona-enabled delivery - p. S5 22. Chapter Eighteen. Overview of protein corona formation and implications - p. 515 23. Chapter Nineteen. Protein corona-mediated targeted delivery - p. 531 24. Chapter Twenty. Protein corona–enabled cloaking systems for drug delivery - p. 561 25. Chapter Twenty one. Harnessing the protein corona for brain targeted delivery - p. 573 26. Section 6. Cell-based drug delivery - p. S6 27. Chapter Twenty Two. Stem cell-based drug delivery system - p. 621 28. Chapter Twenty Three. Leukocyte-targeting drug delivery systems - p. 645 29. Chapter Twenty Four. Large peritoneal macrophage tropism for targeted delivery - p. 675 30. Chapter Twenty Five. Neutrophil-based drug delivery systems - p. 691 31. Chapter Twenty Six. Erythrocyte-based delivery - p. 721 32. Chapter Twenty Seven. Platelet-based drug delivery systems - p. 739 33. Section 7. Cellular “backpacks” - p. S7 34. Chapter Twenty Eight. Cellular backpacks as drug delivery systems - p. 761 35. Chapter Twenty Nine. Immune cell backpacks - p. 797 36. Chapter Thirty. Red blood cell as a hitchhiking platform for targeted systemic drug delivery - p. 813 37. Section 8. Extracellular vesicles - p. S8 38. Chapter THIRTY One. Extracellular vesicle journey: Cellular secretion, communication, and functions - p. 837 39. Chapter THIRTY Two. Extracellular vesicles for targeted delivery - p. 885 40. Chapter Thirty Three. Surface-engineered extracellular vesicles - p. 913 41. Chapter Thirty Four. Role of bacterial extracellular vesicles in health and diseases - p. 947 42. Section 9. Viral particles for targeted delivery - p. S9 43. Chapter Thirty Five. Engineered viral vectors as tools for therapeutic gene delivery - p. 979 44. Chapter Thirty Six. Targeted delivery using virus-like particles - p. 1019 45. Chapter Thirty Seven. Engineered plant viruses - p. 1055 46. Section 10. Clinical Translation―Challenges and Opportunities - p. S10 47. Chapter Thirty Eight. Manufacturing of complex pharmaceuticals - p. 1071 48. Index - p. 497 49. Index - p. 1131
Harnessing Endogenous Mechanisms for Targeted Drug Delivery presents a comprehensive exploration of the evolving landscape of targeted drug delivery, emphasizing the strategic utilization of the body's intrinsic biological pathways. This authoritative two-volume reference addresses the critical need for precision in therapeutic delivery, overcoming physiological, anatomical, and immunological barriers through innovative endogenous mechanisms. By integrating foundational concepts with advanced methodologies, the work underscores the transition from traditional passive and active targeting to sophisticated endogenous strategies that enhance drug specificity and efficacy.
The text systematically examines the multifaceted challenges inherent in drug delivery, including detailed analyses of in vivo barriers such as the blood-tumor barrier, blood-brain barrier, ocular, pulmonary, and gastrointestinal obstacles, as well as cellular and intracellular impediments. It further elucidates endogenous stimuli-responsive systems, nutrient transporter exploitation, glyco-targeting, and stealth peptide modifications. Comprehensive coverage extends to drug conjugates, protein corona phenomena, and cell-based delivery platforms encompassing stem cells, leukocytes, erythrocytes, and platelets. The series also addresses extracellular vesicles, viral vectors, and plant virus-based carriers, culminating in critical discussions on manufacturing complexities, regulatory considerations, and clinical translation challenges.
This definitive resource is indispensable for graduate students, postdoctoral researchers, and professionals in academia and industry engaged in targeted drug delivery research and development. By providing an in-depth understanding of endogenous targeting mechanisms and their translational potential, the book fosters innovation and supports the advancement of precision therapeutics with the goal of improving patient outcomes.
1. Chapter One. Introduction and impact statement - p. 3 2. Chapter Two. Challenges and opportunities in targeted delivery - p. 5 3. Section 2. Delivery barriers - p. S2 4. Chapter Three. Blood–tumor barriers - p. 15 5. Chapter Four. The blood–brain barrier - p. 49 6. Chapter Five. Overcoming ocular barriers for effective drug delivery - p. 85 7. Chapter Six. Pulmonary barriers to targeted delivery - p. 111 8. Chapter Seven. Exploiting gastrointestinal barriers for targeted drug delivery - p. 149 9. Chapter Eight. Cellular and intracellular barriers for drug delivery - p. 189 10. Section 3. Endogenous targeting strategies - p. S3 11. Chapter Nine. Overview of endogenous targeted delivery strategies - p. 219 12. Chapter Ten. Endogenous pH alterations for precision drug delivery - p. 267 13. Chapter Eleven. Hypoxia responsive delivery systems - p. 307 14. Chapter Twelve. Redox-responsive micellar drug delivery systems - p. 341 15. Chapter Thirteen. Nutrient transporter-targeted drug delivery - p. 361 16. Chapter Fourteen. Glyco-targeted delivery systems - p. 395 17. Chapter Fifteen. Surface-modified delivery systems for stealth function - p. 421 18. Section 4. Drug conjugates - p. S4 19. Chapter sixteen. Therapeutic exploitation of the neonatal Fc receptor in albumin-based drug designs - p. 443 20. Chapter Seventeen. Lectin conjugates for targeted delivery - p. 471 21. Section 5. Protein corona-enabled delivery - p. S5 22. Chapter Eighteen. Overview of protein corona formation and implications - p. 515 23. Chapter Nineteen. Protein corona-mediated targeted delivery - p. 531 24. Chapter Twenty. Protein corona–enabled cloaking systems for drug delivery - p. 561 25. Chapter Twenty one. Harnessing the protein corona for brain targeted delivery - p. 573 26. Section 6. Cell-based drug delivery - p. S6 27. Chapter Twenty Two. Stem cell-based drug delivery system - p. 621 28. Chapter Twenty Three. Leukocyte-targeting drug delivery systems - p. 645 29. Chapter Twenty Four. Large peritoneal macrophage tropism for targeted delivery - p. 675 30. Chapter Twenty Five. Neutrophil-based drug delivery systems - p. 691 31. Chapter Twenty Six. Erythrocyte-based delivery - p. 721 32. Chapter Twenty Seven. Platelet-based drug delivery systems - p. 739 33. Section 7. Cellular “backpacks” - p. S7 34. Chapter Twenty Eight. Cellular backpacks as drug delivery systems - p. 761 35. Chapter Twenty Nine. Immune cell backpacks - p. 797 36. Chapter Thirty. Red blood cell as a hitchhiking platform for targeted systemic drug delivery - p. 813 37. Section 8. Extracellular vesicles - p. S8 38. Chapter THIRTY One. Extracellular vesicle journey: Cellular secretion, communication, and functions - p. 837 39. Chapter THIRTY Two. Extracellular vesicles for targeted delivery - p. 885 40. Chapter Thirty Three. Surface-engineered extracellular vesicles - p. 913 41. Chapter Thirty Four. Role of bacterial extracellular vesicles in health and diseases - p. 947 42. Section 9. Viral particles for targeted delivery - p. S9 43. Chapter Thirty Five. Engineered viral vectors as tools for therapeutic gene delivery - p. 979 44. Chapter Thirty Six. Targeted delivery using virus-like particles - p. 1019 45. Chapter Thirty Seven. Engineered plant viruses - p. 1055 46. Section 10. Clinical Translation―Challenges and Opportunities - p. S10 47. Chapter Thirty Eight. Manufacturing of complex pharmaceuticals - p. 1071 48. Index - p. 497 49. Index - p. 1131
